Commerzbank Aktiengesellschaft FI Purchases 11,598 Shares of Stryker Corporation $SYK

Key Points

• Commerzbank Aktiengesellschaft FI increased its Stryker stake by 83.3% in the second quarter, purchasing 11,598 additional shares and bringing its holdings to 25,526 shares valued at approximately $8.04 million.
• Stryker reported quarterly EPS of $3.69, exceeding estimates of $3.49, while revenue rose 9.4% year over year to $6.59 billion. The company also declared a quarterly dividend of $0.88 per share, equivalent to a 1.1% annual yield.
• Analysts maintain a generally positive view, with a consensus rating of “Moderate Buy” and an average price target of $386.28, although recent insider sales included 310,000 shares sold by director Ronda E. Stryker.

Commerzbank Aktiengesellschaft FI lifted its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 83.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,526 shares of the medical technology company's stock after buying an additional 11,598 shares during the quarter. Commerzbank Aktiengesellschaft FI's holdings in Stryker were worth $8,037,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC lifted its position in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. acquired a new stake in Stryker in the 2nd quarter worth approximately $205,000. Marshall Wace LLP lifted its stake in shares of Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company's stock worth $2,255,000 after buying an additional 77,831 shares during the period. Nebula Research & Development LLC purchased a new stake in Stryker during the 2nd quarter valued at about $219,000. Finally, HUB Investment Partners LLC acquired a new position in Stryker in the 2nd quarter worth approximately $253,000. Institutional investors own 77.09% of the company's stock.

Stryker Trading Down 2.2%

NYSE:SYK opened at $331.75 on Tuesday. The firm has a market cap of $127.25 billion, a P/E ratio of 34.38, a PEG ratio of 2.16 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The stock's 50 day simple moving average is $325.21 and its 200-day simple moving average is $333.24.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the prior year, the business posted $3.13 EPS. The company's revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts anticipate that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 36.48%.

Insider Transactions at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares of the company's stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company's stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company's stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 4.60% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. The Goldman Sachs Group restated a "neutral" rating and set a $361.00 price target on shares of Stryker in a research report on Friday, May 1st. UBS Group started coverage on shares of Stryker in a research note on Tuesday, July 28th. They set a "buy" rating and a $400.00 target price on the stock. JPMorgan Chase & Co. decreased their price target on Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a research note on Friday, July 31st. BMO Capital Markets initiated coverage on shares of Stryker in a research report on Wednesday, July 8th. They set an "outperform" rating and a $369.00 price objective for the company. Finally, Royal Bank Of Canada lowered their target price on Stryker from $435.00 to $420.00 and set an "outperform" rating for the company in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source